Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

Wolfe Research argues that despite a near-term impact, large-cap U.S. pharma stocks are largely immune from the anti-chronic ...

Citigroup initiated coverage on shares of Biogen (NASDAQ:BIIB – Get Free Report) in a report issued on Thursday, MarketBeat ...

Los Angeles Capital Management LLC bought a new stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) in the third ...

EMA committee recommends approval of Eisai & Biogen’s lecanemab to treat early Alzheimer’s disease: Tokyo Saturday, November 16, 2024, 13:00 Hrs [IST] Eisai Co., Ltd. and Biog ...

Denali Therapeutics' innovative approach to neurological disorders and strong financial strategy position it as a leader in ...

Lecanemab is the first treatment for Alzheimer’s disease licensed for use in Great Britain that shows some evidence of ...

A groundbreaking medication designed to delay the onset of Alzheimer's has received approval for use within the EU. The drug, ...

On Thursday, the EMA (European Medicines Agency) approved the long-awaited treatment after initially blocking it in July, ...

A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins in the brains of sufferers of the debilitating disease, will cost 3.08 ...

Biogen has taken up an option on a technology developed by Denali that it thinks could help improve the safety and efficacy of amyloid-targeting drugs for Alzheimer’s disease. The technology ...

GRAND JUNCTION, Colo. ( KREX) – A head-on collision affected traffic Friday night at North Avenue and 12th Street. Around ...